These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 19775601)

  • 21. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
    Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
    J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRCA in breast cancer: from risk assessment to therapeutic prediction.
    Diamond JR; Borges VF; Eckhardt SG; Jimeno A
    Drug News Perspect; 2009 Dec; 22(10):603-8. PubMed ID: 20140280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes.
    Melchor L; Benítez J
    Carcinogenesis; 2008 Aug; 29(8):1475-82. PubMed ID: 18596026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
    Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
    Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes.
    Melchor L; Honrado E; García MJ; Alvarez S; Palacios J; Osorio A; Nathanson KL; Benítez J
    Oncogene; 2008 May; 27(22):3165-75. PubMed ID: 18071313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.
    Williams DJ; Cohen C; To TV; Page AJ; Lawson D; Sussman ZM; Nassar A
    Hum Pathol; 2009 Aug; 40(8):1176-81. PubMed ID: 19368951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
    Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
    Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
    Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
    Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metastatic triple-negative breast cancer.
    Rakha EA; Chan S
    Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):587-600. PubMed ID: 21524569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance.
    Kobayashi S
    Breast Cancer; 2008; 15(2):153-8. PubMed ID: 18311481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triple-negative breast cancer: current state of the art.
    Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
    Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathological definition of triple negative breast cancer.
    Viale G; Bottiglieri L
    Eur J Cancer; 2009 Sep; 45 Suppl 1():5-10. PubMed ID: 19775600
    [No Abstract]   [Full Text] [Related]  

  • 34. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
    Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
    J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
    Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer.
    Pinilla SM; Honrado E; Hardisson D; Benítez J; Palacios J
    Breast Cancer Res Treat; 2006 Sep; 99(1):85-90. PubMed ID: 16541313
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
    Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
    Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer.
    Greenberg S; Rugo HS
    Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S20-9. PubMed ID: 20805062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.